{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:23:33Z","timestamp":1783124613828,"version":"3.54.6"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["T32 AG057461"],"award-info":[{"award-number":["T32 AG057461"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30 AG072946"],"award-info":[{"award-number":["P30 AG072946"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R24 AG064025"],"award-info":[{"award-number":["R24 AG064025"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>This study aimed to examine gabapentin utilization trends among older adults with different cognitive statuses and investigate concurrent medication use of potentially inappropriate medications. Data were extracted from the National Alzheimer's Coordinating Center Uniform Data Set (2006\u20132019). We estimated the yearly prevalence of gabapentin use, both overall and within subgroups defined by cognitive status (normal, mild cognitive impairment and dementia) and demographics (age and sex) for participants aged 65+. Additionally, we assessed the prevalence of concurrent use of gabapentin with opioids, combined opioids and benzodiazepine, antidepressant and antipsychotic. From 35\u2009205 eligible older adults (mean age [SD]: 75.7 [7.0]; male: 43.1%), gabapentin use increased from 2006 to 2019 in both overall and every participant subgroup. About 10%\u201330% of gabapentin users reported to concurrently use opioids, and the concurrent use of gabapentin, opioid and benzodiazepine was up to 7.5% throughout the study period. The frequency of concurrent use with antipsychotics or antidepressants was higher in participants with dementia than those with normal cognition or those who were mildly cognitively impaired. Given increasing use among older adults, rigorous studies are needed to examine the safety of gabapentin in this population.<\/jats:p>","DOI":"10.1111\/bcp.15532","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T07:33:51Z","timestamp":1663054431000},"page":"410-415","source":"Crossref","is-referenced-by-count":14,"title":["Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer's Coordinating Center (2006\u20132019)"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7203-8460","authenticated-orcid":false,"given":"G Yeon","family":"Oh","sequence":"first","affiliation":[{"name":"Sanders\u2010Brown Center on Aging University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-8197","authenticated-orcid":false,"given":"Daniela C.","family":"Moga","sequence":"additional","affiliation":[{"name":"Sanders\u2010Brown Center on Aging University of Kentucky  Lexington Kentucky USA"},{"name":"Department of Epidemiology University of Kentucky  Lexington Kentucky USA"},{"name":"Department of Pharmacy Practice and Science University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-4111","authenticated-orcid":false,"given":"Erin L.","family":"Abner","sequence":"additional","affiliation":[{"name":"Sanders\u2010Brown Center on Aging University of Kentucky  Lexington Kentucky USA"},{"name":"Department of Epidemiology University of Kentucky  Lexington Kentucky USA"},{"name":"Department of Biostatistics University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Pfizer.FDA approval labeling neurontin.2017.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020235s064_020882s047_021129s046lbl.pdf. Accessed July 20 2022."},{"key":"e_1_2_10_3_1","unstructured":"European Medicines Agency.Neurontin.2006.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/neurontin. Accessed July 20 2022."},{"key":"e_1_2_10_4_1","unstructured":"Electronic Medicines Compendium.Neurontin.https:\/\/www.medicines.org.uk\/emc\/product\/3195\/smpc#gref. Accessed July 20 2022."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1178221818801311"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3821\/145.6.cpj280"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2002.8.4.266"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.11.003"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7856"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.01.018"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001432\u20107"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122\u2010020\u201000189\u2010x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100302"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102021\u2010052057"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15189"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S168504"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4441"},{"key":"e_1_2_10_18_1","unstructured":"U.S. Food and Drug Administration.FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin Gralise Horizant) and pregabalin (Lyrica Lyrica CR).2019.https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Accessed September 18 2022."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15767"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512\u2010200825030\u201000002"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41394\u2010018\u20100038\u2010y"},{"issue":"4","key":"e_1_2_10_22_1","first-page":"270","article-title":"The National Alzheimer's Coordinating Center (NACC) database: an Alzheimer disease database","volume":"18","author":"Beekly DL","year":"2004","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wad.0000213865.09806.92"},{"issue":"4","key":"e_1_2_10_24_1","first-page":"305","article-title":"Five ways you can reduce inappropriate prescribing in the elderly: a systematic review","volume":"55","author":"Garcia RM","year":"2006","journal-title":"J Fam Pract"},{"key":"e_1_2_10_25_1","unstructured":"The National Alzheimer's Coordinating Center.NACC Uniform Data Set researchers data dictionary.2015.https:\/\/files.alz.washington.edu\/documentation\/uds3-rdd.pdf. Accessed September 18 2022."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.3.246"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000338"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.11.033"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1195"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7119a3"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15532","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15532","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T11:24:34Z","timestamp":1692444274000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/bcp.15532"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15532","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}